T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment
November 15, 2023 02:00 ET
|
T-Therapeutics
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis...
BioMed X Launches New T Cell Immunology Discovery Platform
February 14, 2023 06:00 ET
|
BioMed X Institute (990552)
HEIDELBERG, Germany, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BioMed X announced today the launch of its new immunology discovery platform that will allow for the accurate and fast identification of target...
$32.4 Bn Cell Therapy Instruments Market to Exhibit CAGR of 13.2% by 2027, Deep Dive Analysis of Key Players and Growth Opportunities
November 15, 2022 08:17 ET
|
The Insight Partners
New York, Nov. 15, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "Cell Therapy Instrument Market Size, Share, Growth, Trends and Forecast to 2027 – COVID-19 Impact and...
T-Cell Therapy Market Size to Hit $21+ Billion with Booming CAGR Value of 20.7% by 2028 | The Insight Partners
October 20, 2022 09:22 ET
|
The Insight Partners
New York, Oct. 20, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "T-cell Therapy Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact and...
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
December 12, 2021 09:05 ET
|
Sana Biotechnology, Inc
Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional...
Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021
April 27, 2021 16:35 ET
|
Sana Biotechnology, Inc
— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes — SEATTLE, April 27, 2021 (GLOBE NEWSWIRE)...
Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021
April 09, 2021 09:00 ET
|
Sana Biotechnology, Inc
– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogenresults in tumor eradication –– Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in...
Notch Therapeutics – a new company with a revolutionary allogeneic ("off the shelf") T cell technology
November 05, 2019 06:00 ET
|
Notch Therapeutics
Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that...
ARTICLE COMPARING SURVIVAL OUTCOMES OF ISOLATED LIMB INFUSION VERSUS PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
January 29, 2019 08:30 ET
|
Provectus Biopharmaceuticals Inc.
- 72 patients were treated with either ILI or PV-10 at Australia’s Princess Alexandra Hospital; data were prospectively recorded; primary outcome was melanoma-specific survival; ILI is historical...